All publications

Export 6 results:
Author Title Type [ Year(Asc)]
Filters: First Letter Of Title is S  [Clear All Filters]
2017
Mbisa JL, Kirwan P, Bibby D., Brown A, Myers R.E, Murphy G., Ledesma J, Asboe D, Pozniak A, Sabin CA et al..  2017.  Source of HIV-1 drug-resistant minority variants in people who are recently infected. BHIVA Spring.
Mbisa JL, Kirwan P, Bibby D., Brown A, Myers R.E, Murphy G., Ledesma J, Asboe D, Pozniak A, Sabin CA et al..  2017.  Source of HIV-1 drug-resistant minority variants in people who are recently infected. 24th International HIV Dynamics and Evolution.
2014
Mbisa JL, Fearnhill E, Dunn DT, Pillay D, Cane P A, UK HIV Drug Resistance Database.  2014.  Sustained Spread of HIV-1 Drug Resistance in Treatment-Naïve Patients in the United Kingdom. Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014.
2013
Waters L., Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn DT, Phillips AN.  2013.  Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone. Antivir Ther. 18:213-9.
Koning FA, Castro H, Dunn DT, Tilston P, Cane P A, Mbisa JL.  2013.  Subtype-specific differences in the development of accessory mutations associated with high-level resistance to HIV-1 nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother. 68:1220-36.
2012
Koning FA, Castro H, Dunn DT, Mbisa JL, Cane P A, UK HIV Drug Resistance Database.  2012.  Significant HIV-1 subtype differences observed in the development of accessory mutations associated with high-level resistance to reverse transcriptase inhibitors. International Workshop on HIV & Hepatitis Virus Resistance and Curative Strategies, 5-9 June 2012. Antiviral Therapy 17 Suppl 1:A84.